Axios: “The University of Oxford announced Monday a COVID-19 vaccine it’s developed with AstraZeneca is 70.4% effective in preventing people from developing symptoms, per interim data from phase 3 trials. Of note: The findings come from combining results from two different dosing regimes. When two full doses were given to volunteers at least a month apart, the efficacy was 62%. This rose to 90% among those given half a dose, followed by a full one, the university noted in a statement. Pfizer and Moderna both reported earlier this month their coronavirus vaccines had efficacy rates of about 95%.”